跳至主要内容
临床试验/NCT00081731
NCT00081731已完成3 期

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

Baim Institute for Clinical Research1 个研究点 分布在 1 个国家目标入组 947 人开始时间: 2004年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
947
试验地点
1
主要终点
Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy

研究概览

简要总结

This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.

详细描述

BACKGROUND:

Atherosclerotic renal artery stenosis is a common problem for which there is no clear consensus on diagnosis or therapy. There likely exists a progression in which renal ischemia leads to neuroendocrine activation, hypertension, and renal insufficiency resulting in acceleration of atherosclerosis, further renal dysfunction, and development of left ventricular hypertrophy. These events in turn lead to adverse clinical events.

Renal artery stenosis is one of the two major known causes of hypertension and occurs in 1-5% of hypertensive patients. In patients with accelerated hypertension, the prevalence of renal artery stenosis is much higher, ranging from 10-40%. Renal artery stenosis, when occurring bilaterally, or in a solitary kidney, is a significant cause for end-stage renal disease, accounting for several percent of patients with end-stage renal disease. Clinically, atherosclerotic renal artery stenosis is a major problem primarily in older patients, and is often seen in long-standing hypertensives whose blood pressure becomes very difficult to control. Of major significance is the progressive nature of atherosclerotic renal artery stenosis, progressing at the rate of about 10% per year (45-60% progression rate in 4-7 year follow-ups). Over this time period, 10-15% of patients develop total renal artery occlusion. If the renal artery stenosis is greater than 75% when detected, 40% of patients develop total occlusion. Due to the progressive nature of atherosclerotic lesions, the decline in renal function in some individuals, and difficult-to-control hypertension, the medical community has sought to detect those patients in whom intervention would be beneficial. This has been extremely difficult to achieve and tests to date have not been uniformly predictive, including peripheral vein plasma renin activity, renal vein renin activity, captopril-stimulated nuclear medicine renal scans, etc.

Since approximately 50% of patients with unilateral renal artery stenosis of significant degree (definitions vary) benefit from surgical intervention, enthusiasm has continued with the advent of renal artery angioplasty. The entire field is moving very quickly. However, there are neither current data nor prospective studies indicating the benefit of renal artery angioplasty plus stents. Studies over the last decade have shown that balloon angioplasty alone is associated with a high rate of recurrence in patients with atherosclerotic renal artery stenosis. In the present climate, there is great enthusiasm to perform angioplasty plus stent placement in atherosclerotic renal artery stenosis, without supporting data for efficacy compared to medical management alone. Angioplasty and stent placement in the renal arteries had been the domain of interventional radiologists, but recently, interventional cardiologists are also performing these procedures. The questions as to who will benefit from intervention and which intervention to use have not been answered. Renal artery angioplasty and stent placement subjects the patient to procedural risks, as well as increased cost, when compared to aggressive antihypertensive medication and risk factor medication and therapy.

DESIGN NARRATIVE:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Optimal Medical Therapy

Active Comparator

Optimal anti-hypertensive therapy

干预措施: Atacand/HCT, Caduet (Drug)

Stenting

Experimental

Stent procedure plus optimal anti-hypertensive therapy

干预措施: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) (Procedure)

结局指标

主要结局

Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy

时间窗: Measured at every 3 months for the first year and annually thereafter

Only the first event per participant is included in the composite

Cardiovascular or Renal Death

时间窗: Measured at every 3 months for the first year and annually thereafter

Myocardial Infarction

时间窗: Measured at every 3 months for the first year and annually thereafter

Hospitalization for Congestive Heart Failure

时间窗: Measured at every 3 months for the first year and annually thereafter

Stroke

时间窗: Measured at every 3 months for the first year and annually thereafter

30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days

时间窗: Measured at every 3 months for the first year and annually thereafter

Need for Renal Replacement Therapy

时间窗: Measured at every 3 months for the first year and annually thereafter

次要结局

未报告次要终点

研究者

发起方
Baim Institute for Clinical Research
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验